156 results on '"Mfinanga, S"'
Search Results
2. Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis
- Author
-
Mnyambwa, N. P., Kim, D.-J., Ngadaya, E. S., Kazwala, R., Petrucka, P., and Mfinanga, S. G.
- Published
- 2017
- Full Text
- View/download PDF
3. IPT coverage and determinants of care coverage in Tanzania
- Author
-
Manisha, H., primary, Amani, W., additional, Garrib, A., additional, Senkoro, M., additional, and Mfinanga, S., additional
- Published
- 2022
- Full Text
- View/download PDF
4. National tuberculosis prevalence surveys in Africa, 2008–2016: an overview of results and lessons learned
- Author
-
Law I., Floyd K., Abukaraig E. A. B., Addo K. K., Adetifa I., Alebachew Z., Banda R., Bashorun A., Bloss E., Bonsu F. A., Chanda-Kapata P., Demba E., Elegail A. M. A. S., Eltigany M., Ershova J., Gasana M., Girma B., Glaziou P., Kalisvaart N., Hamadelneel H. K., Kamara D., Kapata N., Kasozi S., Kebede A., Kendall L., Kipruto H., Kirenga B. J., Klinkenberg E., Kobayashi S., Linda C., Masini E., Matambo R., Mfinanga S., Migambi P., Moonan P., Mpunga J., Mugabe F., Munthali A., Mutsvangwa J., Nkhoma W., Obasanya J., Omoleke S., Onozaki I., Patrobas P., Ong'ang'o J. R., Rutebemberwa E., Sandy C., Senkoro M., Sismanidis C., Sitienei J., Tadolini M., Timimi H., Tsegaye F., Uwizeye C. B., Yamada N., Law I., Floyd K., Abukaraig E.A.B., Addo K.K., Adetifa I., Alebachew Z., Banda R., Bashorun A., Bloss E., Bonsu F.A., Chanda-Kapata P., Demba E., Elegail A.M.A.S., Eltigany M., Ershova J., Gasana M., Girma B., Glaziou P., Kalisvaart N., Hamadelneel H.K., Kamara D., Kapata N., Kasozi S., Kebede A., Kendall L., Kipruto H., Kirenga B.J., Klinkenberg E., Kobayashi S., Linda C., Masini E., Matambo R., Mfinanga S., Migambi P., Moonan P., Mpunga J., Mugabe F., Munthali A., Mutsvangwa J., Nkhoma W., Obasanya J., Omoleke S., Onozaki I., Patrobas P., Ong'ang'o J.R., Rutebemberwa E., Sandy C., Senkoro M., Sismanidis C., Sitienei J., Tadolini M., Timimi H., Tsegaye F., Uwizeye C.B., Yamada N., APH - Global Health, and Global Health
- Subjects
Adult ,Male ,Tuberculosis ,Adolescent ,HIV Infections ,Article ,Global Burden of Disease ,Young Adult ,Sex Factors ,prevalence survey ,Surveys and Questionnaires ,medicine ,Prevalence ,Humans ,Mass Screening ,Disease Notification ,Aged ,Aged, 80 and over ,public health ,Public Health, Environmental and Occupational Health ,Prevalence survey ,Middle Aged ,medicine.disease ,Infectious Diseases ,Geography ,Africa ,Parasitology ,Female ,epidemiology ,Humanities - Abstract
Objective and Methods In many countries, national tuberculosis (TB) prevalence surveys are the only way to reliably measure the burden of TB disease and monitor trends. They can also provide evidence about the current performance of TB care and control and how this could be improved. We developed an inventory of Asian surveys from 1953 to 2012 and then compiled and analysed a standard set of data for all national surveys implemented between 1990 (the baseline year for 2015 global TB targets) and 2012. Results There were 21 surveys in 12 countries between 1990 and 2012; published results were available for 18. The participation rate was at least 80% and often much higher except for two surveys in Thailand. The prevalence of bacteriologically-positive TB disease among adults aged ≥15 years varied widely among countries (1.2 per 1000 population in China in 2010 to 15 per 1000 population in Cambodia in 2002), but age and sex distribution patterns were consistent with a progressive increase in rates of disease by age, and men accounting for 66–75% of prevalent cases. A high proportion of cases (40–79% across all surveys) did not report TB symptoms that met screening criteria (generally cough of 2–3 weeks or more, and blood in the sputum) and were only detected due to chest X-ray screening of all survey participants; this proportion increased over time in countries with repeat survey data. The ratio of prevalent cases to cases notified to national TB programmes was typically around two, but was as high as three in Lao PDR and Pakistan even after the internationally recommended TB control strategy had been implemented nationwide for several years. Four countries (China, Cambodia, the Republic of Korea and the Philippines demonstrated declines in smear or culture-positive pulmonary TB prevalence of approximately 50% over 10 years. Conclusions National TB prevalence surveys in Asia show that large reductions in the prevalence of TB disease can be achieved within a decade, that men bear much more of the burden than women and that the epidemic is ageing. Comparisons among countries show that more can be achieved in TB control in some countries with existing strategies and technologies. However, with many prevalent cases not reporting classic TB symptoms, all countries face the challenge of defining and implementing strategies that will result in earlier detection and treatment of cases. Objectifs et methodes Dans de nombreux pays, les enquetes de prevalence nationale de la TB sont le seul moyen de mesurer de maniere fiable la charge de morbidite de la TB et de suivre les tendances. Elles peuvent aussi fournir des donnees sur la performance actuelle des soins et la lutte antituberculeuse et comment cela pourrait etre ameliore. Nous avons etabli un inventaire des enquetes d'Asie de 1953 a 2012 et avons ensuite compile et analyse un ensemble standard de donnees pour toutes les enquetes nationales effectuees entre 1990 (annee de reference pour les objectifs mondiaux 2015 de la TB) et 2012. Resultats Il y a eu 21 enquetes dans 12 pays entre 1990 et 2012; des resultats publies etaient disponibles pour 18 enquetes. Le taux de participation etait d'au moins 80% et souvent beaucoup plus, sauf pour deux enquetes en Thailande. La prevalence de la TB bacteriologiquement positive chez les adultes âges de ≥15 ans variait considerablement entre les pays (de 1,2 pour 1000 habitants en Chine en 2010 a 15 pour 1000 habitants au Cambodge en 2002), mais les profils de distribution selon l’âge et le sexe etaient compatibles avec une augmentation progressive des taux de la maladie selon l’âge, les hommes representant 66 a 75% des cas prevalents. Une forte proportion des cas (40 a 79% dans toutes les enquetes) n'a pas rapporte des symptomes de TB repondant aux criteres de depistage (generalement, de la toux pendant 2 a 3 semaines ou plus et du sang dans les crachats), et ont seulement ete detectes grâce au depistage par la radiographie du thorax de tous les participants a l'enquete; cette proportion a augmente au fil du temps dans les pays avec des donnees repetitives de l'enquete. Le rapport des cas prevalents sur les cas notifies aux programmes nationaux de lutte antituberculeuse etait generalement autour de 2, mais etait aussi eleve que 3 en Republique Democratique Populaire Lao et au Pakistan, meme apres que la strategie de lutte antituberculeuse internationalement recommandee ait ete implementee a l’echelle nationale depuis plusieurs annees. Quatre pays (la Chine, le Cambodge, les Philippines et la Republique de Coree) ont connu une baisse de prevalence de la TB pulmonaire a frottis ou culture positive d'environ 50% sur 10 ans. Conclusions Les enquetes de prevalence nationale de la TB en Asie montrent que de fortes reductions de la prevalence de la TB peuvent etre atteintes en une decennie, que les hommes portent beaucoup plus la charge que les femmes et que l’epidemie est vieillissante. Les comparaisons entre pays montrent que plus d'efforts pourraient etre realises dans certains pays dans la lutte antituberculeuse avec les strategies et les technologies existantes. Cependant, avec les nombreux cas prevalents qui ne rapportent pas les symptomes classiques de la TB, tous les pays sont confrontes au defi de definir et mettre en œuvre des strategies qui resulteront en la detection et au traitement des cas plus tot. Objetivos y Metodos En muchos paises, las encuestas sobre la prevalencia de la TB son la unica forma confiable de medir la carga de enfermedad por TB y monitorizar las tendencias. Tambien pueden proveer evidencia sobre el desempeno actual de los cuidados para y el control de la TB y de como podrian mejorarse. Hemos desarrollado un inventario de las encuestas asiaticas realizadas entre 1953 y el 2012 y despues compilamos y analizamos un set de datos estandar para todas encuestas nacionales implementadas entre 1990 (el ano de base para los objetivos globales de TB del 2015) y el 2012. Resultados Se detectaron 21 encuestas en 12 paises entre 1990 y 2012; 18 de ellas tenian resultados publicados. La tasa de participacion era de al menos el 80% y a menudo mucho mas alta excepto para las dos encuestas de Tailandia. La prevalencia de enfermedad tuberculosa con resultados bacteriologicos positivos entre adultos ≥15 anos variaba ampliamente entre paises (1.2 por 1000 habitantes en China en 2010 a 15 por 1000 habitantes en Camboya en 2002), pero los patrones de distribucion por edad y sexo eran consistentes con un aumento progresivo en las tasas de incidencia por edad, y en que un 66−75% de los casos prevalentes eran en hombres. Una alta proporcion de casos (40−79% a lo largo de todas las encuestas) no reportaban sintomas de TB contemplados como criterios de cribado (generalmente tos de 2−3 semanas o mas, y sangre en el esputo), y solo se detectaron mediante una placa de torax realizada a todos los participantes del estudio; esta proporcion aumentaba a lo largo del tiempo en paises con datos de encuestas repetidas. La proporcion de casos prevalentes frente a casos notificados al programa nacional de TB era tipicamente alrededor de dos, pero llegaba incluso a tres en Lao PDR y Paquistan, incluso varios anos despues de la implementacion de la estrategia de control de la TB recomendada a nivel internacional. Cuatro paises (China, Camboya, Filipinas y la Republica de Corea) mostraron una disminucion en la prevalencia de TB pulmonar con baciloscopia o cultivo positivo de aproximadamente un 50% a lo largo de 10 anos. Conclusiones Las encuestas nacionales de prevalencia de la TB en Asia muestran que se pueden alcanzar grandes reducciones en la prevalencia de la enfermedad tuberculosa a lo largo de una decada, que los hombres tienen una mayor carga de enfermedad que las mujeres y que la epidemia esta envejeciendo. Las comparaciones entre paises muestran que se podria lograr mucho mas en el control de la TB en algunos paises con estrategias y tecnologias existentes. Sin embargo, con muchos casos prevalentes que no presentan los sintomas clasicos de la TB, todos los paises se enfrentan al reto de definir e implementar estrategias que resulten en una deteccion y tratamiento de los casos mas temprano.
- Published
- 2020
5. Antibiotic Susceptibility Patterns of Bacterial Isolates from Routine Clinical Specimens from Referral Hospitals in Tanzania: A Prospective Hospital-Based Observational Study
- Author
-
Mnyambwa NP, Mahende C, Wilfred A, Sandi E, Mgina N, Lubinza C, Kahwa A, Petrucka P, Mfinanga S, Ngadaya E, and Kimaro G
- Subjects
antimicrobial resistance (amr) ,antibiotic susceptibility testing ,bacterial isolates ,methicillin-resistant staphylococcus aureus (mrsa) ,lcsh:RC109-216 ,antibiotics ,lcsh:Infectious and parasitic diseases - Abstract
Nicholaus P Mnyambwa,1 Coline Mahende,1 Amani Wilfred,1 Erica Sandi,1 Nicodem Mgina,2 Clara Lubinza,1 Amos Kahwa,1 Pammla Petrucka,3,4 Sayoki Mfinanga,1,3,5 Esther Ngadaya,1 Godfather Kimaro1 1National Institute for Medical Research, Muhimbili Research Centre, Dar es Salaam, Tanzania; 2Central Tuberculosis Reference Laboratory (CTRL), Dar es Salaam, Tanzania; 3School of Life Science and Bioengineering, Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania; 4University of Saskatchewan, Saskatoon, Canada; 5Department of Epidemiology and Statistics, Muhimbili University of Health and Allied Sciences, Dar es Salaam, TanzaniaCorrespondence: Nicholaus P MnyambwaNational Institute for Medical Research Muhimbili Research Centre, P. O. Box 447, Dar es Salaam, TanzaniaEmail lodnicho@gmail.comIntroduction: Antimicrobial resistance is one of the biggest threats of modern public health. Although sub-Saharan Africa is highly burdened with infectious diseases, current data on antimicrobial resistance are sparse.Methods: A prospective study was conducted between October 2018 and September 2019 to assess the antibiotic susceptibility patterns of clinical bacterial isolates obtained from four referral hospitals in Tanzania. We used standard media and Kirby-Bauer disc diffusion methods as per Clinical and Laboratory Standards Institute (CLSI) standards.Results: We processed a total of 2620 specimens of which 388 (14.8%) were culture-positive from patients with a median (IQR) age of 28 (12– 44) years. Of the positive cultures, 52.3% (203) were from females. Most collected specimens were ear pus 28.6% (111), urine 24.0% (93), wound pus 20.6% (80), stool 14.9% (58), and blood 8.3% (32). Predominant isolates were S. aureus 28.4% (110), E. coli 15.2% (59), P. aeruginosa 10.6% (41), P. mirabilis 7.0% (27), V. cholerae 01 Ogawa 6.2% (24), Klebsiella spp. 5.2% (20) and Streptococcus spp. 4.6% (18). Generally, the isolates exhibited a high level of resistance to commonly used antibiotics such as Ampicillin, Amoxicillin-Clavulanic acid, Erythromycin, Gentamicin, Tetracycline, Trimethoprim, third-generation Cephalosporins (Ceftriaxone and Ceftazidime), and reserved drugs (Clindamycin and Meropenem). S. aureus isolates were resistant to most of the antibiotics tested; 66.7% were classified as MRSA infections.Conclusion: Antibiotic resistance to commonly prescribed antibiotics was alarmingly high. Our findings emphasize the need for comprehensive national control programs to combat antibiotic resistance.Keywords: antibiotics, antimicrobial resistance, AMR, antibiotic susceptibility testing, methicillin-resistant Staphylococcus aureus, MRSA, bacterial isolates
- Published
- 2021
6. Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?
- Author
-
Vergeer, S. B., primary, Oldenkamp, R., additional, Senkoro, M., additional, Mfinanga, S., additional, Hinderaker, S. G., additional, and van Leth, F., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?
- Author
-
Vergeer, S. B., Oldenkamp, R., Senkoro, M., Mfinanga, S., Hinderaker, S. G., van Leth, F., Vergeer, S. B., Oldenkamp, R., Senkoro, M., Mfinanga, S., Hinderaker, S. G., and van Leth, F.
- Abstract
BACKGROUND: In high TB burden countries, delayed diagnosis remains a big challenge in TB control. The objective of this study is to assess the role of distance between residence and healthcare facility (HCF) on care-seeking among individuals with symptoms associated with pulmonary TB in Tanzania.METHODS: In this cross-sectional study, using data from a national TB survey, coordinates of 300 (residential) sites within 62 clusters were obtained through Google searches and average distances to HCF were calculated per cluster. Univariable and multivariable logistic regression analyses were conducted, with care-seeking behaviour being the primary outcome variable.RESULTS: Distance from residence to HCF had no effect on care-seeking behaviour of individuals with TB-related symptoms in this study (OR 1.00, 95% CI 1.00-1.00). Over 85% of HCFs where care has been sought lack TB diagnostic capacity, mostly comprising dispensaries with staff less educated in TB-related symptoms.CONCLUSION: Care-seeking behaviour among individuals with TB-related symptoms in Tanzania was not found to be associated with distance to HCF. First-line diagnostics should be improved 1) by equipping local dispensaries with basic TB diagnostic capacity, and 2) by educating staff of local dispensaries more thoroughly about basic TB symptoms and the importance of swift referrals.
- Published
- 2022
- Full Text
- View/download PDF
8. Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease
- Author
-
Mbelele, P. M., primary, Sabiiti, W., additional, Heysell, S. K., additional, Sauli, E., additional, Mpolya, E. A., additional, Mfinanga, S., additional, Gillespie, S. H., additional, Addo, K. K., additional, Kibiki, G., additional, Sloan, D. J., additional, and Mpagama, S. G., additional
- Published
- 2022
- Full Text
- View/download PDF
9. Knowledge, awareness and use of HIV services among the youth from nomadic and agricultural communities in Tanzania
- Author
-
Ngadaya, E., primary, Kimaro, G., additional, Kahwa, A., additional, Mnyambwa, N. P., additional, Shemaghembe, E., additional, Mwenyeheri, T., additional, Wilfred, A., additional, and Mfinanga, S. G., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Xpert® MTB/RIF assay testing on stool for the diagnosis of paediatric pulmonary TB in Tanzania
- Author
-
Ainan, S., primary, Furia, F. F., additional, Mhimbira, F., additional, Mnyambwa, N. P., additional, Mgina, N., additional, Zumla, A., additional, Mfinanga, S. G., additional, and Ngadaya, E., additional
- Published
- 2021
- Full Text
- View/download PDF
11. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology
- Author
-
Hoenigl, M, Salmanton-Garcia, J, Walsh, TJ, Nucci, M, Neoh, CF, Jenks, JD, Lackner, M, Sprute, R, Al-Hatmi, AMS, Bassetti, M, Carlesse, F, Freiberger, T, Koehler, P, Lehrnbecher, T, Kumar, A, Prattes, J, Richardson, M, Revankar, S, Slavin, MA, Stemler, J, Spiess, B, Taj-Aldeen, SJ, Warris, A, Woo, PCY, Young, J-AH, Albus, K, Arenz, D, Arsic-Arsenijevic, V, Bouchara, J-P, Chinniah, TR, Chowdhary, A, de Hoog, GS, Dimopoulos, G, Duarte, RF, Hamal, P, Meis, JF, Mfinanga, S, Queiroz-Telles, F, Patterson, TF, Rahav, G, Rogers, TR, Rotstein, C, Wahyuningsih, R, Seidel, D, Cornely, OA, Hoenigl, M, Salmanton-Garcia, J, Walsh, TJ, Nucci, M, Neoh, CF, Jenks, JD, Lackner, M, Sprute, R, Al-Hatmi, AMS, Bassetti, M, Carlesse, F, Freiberger, T, Koehler, P, Lehrnbecher, T, Kumar, A, Prattes, J, Richardson, M, Revankar, S, Slavin, MA, Stemler, J, Spiess, B, Taj-Aldeen, SJ, Warris, A, Woo, PCY, Young, J-AH, Albus, K, Arenz, D, Arsic-Arsenijevic, V, Bouchara, J-P, Chinniah, TR, Chowdhary, A, de Hoog, GS, Dimopoulos, G, Duarte, RF, Hamal, P, Meis, JF, Mfinanga, S, Queiroz-Telles, F, Patterson, TF, Rahav, G, Rogers, TR, Rotstein, C, Wahyuningsih, R, Seidel, D, and Cornely, OA
- Abstract
With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown effectiveness in preventing many invasive fungal infections, selective pressure has caused an increase of breakthrough infections caused by Fusarium, Lomentospora, and Scedosporium species, as well as by dematiaceous moulds, Rasamsonia, Schizophyllum, Scopulariopsis, Paecilomyces, Penicillium, Talaromyces and Purpureocillium species. Guidance on the complex multidisciplinary management of infections caused by these pathogens has the potential to improve prognosis. Management routes depend on the availability of diagnostic and therapeutic options. The present recommendations are part of the One World-One Guideline initiative to incorporate regional differences in the epidemiology and management of rare mould infections. Experts from 24 countries contributed their knowledge and analysed published evidence on the diagnosis and treatment of rare mould infections. This consensus document intends to provide practical guidance in clinical decision making by engaging physicians and scientists involved in various aspects of clinical management. Moreover, we identify areas of uncertainty and constraints in optimising this management.
- Published
- 2021
12. Priming with a 'simplified regimen' of HIV-1 DNA vaccine is as good as a 'standard regimen' when boosted with heterologous HIV-1 MVA vaccine
- Author
-
Munseri P, Kroidl A, Nilsson C, Moshiro C, Aboud S, Joachim A, Geldmacher C, Aris E, Buma D, Lyamuya E, Gotch F, Godoy-Ramirez K, Pallangyo K, Maboko L, Marovich M, Robb M, Hoelscher M, Janabi M, Mann P, Joseph S, Mfinanga S, Stoehr W, Mhalu F, Wahren B, Biberfeld G, McCormack S, Sandstrom E, and Bakari M
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2012
- Full Text
- View/download PDF
13. COVID-19 and tuberculosis—threats and opportunities
- Author
-
Zumla, Alimuddin, primary, Marais, B. J., additional, McHugh, T. D., additional, Maeurer, M., additional, Zumla, Adam, additional, Kapata, N., additional, Ntoumi, F., additional, Chanda-Kapata, P., additional, Mfinanga, S., additional, Centis, R., additional, Cirillo, D. M., additional, Petersen, E., additional, Hui, D. S, additional, Ippolito, G., additional, Leung, C. C., additional, Migliori, G. B., additional, and Tiberi, S., additional
- Published
- 2020
- Full Text
- View/download PDF
14. Estimates of genetic variability of Mycobacterium tuberculosis complex and its association with drug resistance and treatment outcomes in Tanzania
- Author
-
Mfinanga, S. G.
- Published
- 2010
15. Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa
- Author
-
Chen, T, Mwenge, L, Lakhi, S, Chanda, D, Mwaba, P, Molloy, SF, Gheorghe, A, Griffiths, UK, Heyderman, RS, Kanyama, C, Kouanfack, C, Mfinanga, S, Chan, AK, Temfack, E, Kivuyo, S, Hosseinipour, MC, Lortholary, O, Loyse, A, Jaffar, S, Harrison, TS, Niessen, LW, and ACTA Trial Team
- Subjects
urogenital system ,animal diseases ,parasitic diseases ,technology, industry, and agriculture ,bacterial infections and mycoses - Abstract
Background\ud Mortality from cryptoccocal meningitis remains high. The ACTA trial demonstrated that, compared with 2 weeks of amphotericin B (AmB) plus flucystosine (5FC), 1 week of AmB and 5FC was associated with lower mortality and 2 weeks of oral flucanozole (FLU) plus 5FC was non-inferior. Here, we assess the cost-effectiveness of these different treatment courses.\ud \ud Methods\ud Participants were randomized in a ratio of 2:1:1:1:1 to 2 weeks of oral 5FC and FLU, 1 week of AmB and FLU, 1 week of AmB and 5FC, 2 weeks of AmB and FLU, or 2 weeks of AmB and 5FC in Malawi, Zambia, Cameroon, and Tanzania. Data on individual resource use and health outcomes were collected. Cost-effectiveness was measured as incremental costs per life-year saved, and non-parametric bootstrapping was done.\ud \ud Results\ud Total costs per patient were US $1442 for 2 weeks of oral FLU and 5FC, $1763 for 1 week of AmB and FLU, $1861 for 1 week of AmB and 5FC, $2125 for 2 weeks of AmB and FLU, and $2285 for 2 weeks of AmB and 5FC. Compared to 2 weeks of AmB and 5FC, 1 week of AmB and 5FC was less costly and more effective and 2 weeks of oral FLU and 5FC was less costly and as effective. The incremental cost-effectiveness ratio for 1 week of AmB and 5FC versus oral FLU and 5FC was US $208 (95% confidence interval $91–1210) per life-year saved.\ud \ud Conclusions\ud Both 1 week of AmB and 5FC and 2 weeks of Oral FLU and 5FC are cost-effective treatments.
- Published
- 2019
16. A randomized controlled trial for the treatment of HIV-associated cryptococcal meningitis in Africa: oral fluconazole plus flucytosine or one week amphotericin-based therapy versus two weeks amphotericin-based therapy. The ACTA Trial
- Author
-
Molloy, S, Kanyama, C, Heyderman, R, Loyse, A, Kouanfack, C, Chanda, D, Mfinanga, S, Temfack, E, Lakhi, S, Lesikari, S, Chan, A, Stone, N, Kalata, N, Karunaharan, N, Gaskell, K, Peirse, M, Ellis, J, Chawinga, C, Lontsi, S, Ndong, J-G, Bright, P, Lupiya, D, Chen, T, Bradley, J, Adams, J, van der Horst, C, van Oosterhout, JJ, Sini, V, Mapoure, YN, Mwaba, P, Bicanic, T, Lalloo, D, Wang, D, Hosseinipour, M, Lortholary, O, Jaffar, S, Harrison, T, and Team, ACTATS
- Subjects
bacterial infections and mycoses - Published
- 2017
17. Towards host-directed therapies for tuberculosis [Comment]
- Author
-
Zumla, A., Chakaya, J., Hoelscher,M., Ntoumi, F., Rustomjee, R., Vilaplana, C., Yeboah-Manu, D., Rasolofo, V., Munderi, P., Singh, N., Aklillu, E., Padayatchi, N., Macete, E., Kapata, N., Mulenga, M., Kibiki, G., Mfinanga, S., Nyirenda, T., Maboko, L., Garcia-Basteiro, A., Rakotosamimanana, N., Bates, M., Mwaba, P., Reither, K., Gagneux, S., Edwards, S., Mfinanga, E., Abdulla, S., Cardona, P.J., Russell, J.B.W., Gant, V., Noursadeghi, M., Elkington, P., and Bonnet, Maryline
- Published
- 2016
18. ‘It makes the patient's spirit weaker': tuberculosis stigma and gender interaction in Dar es Salaam, Tanzania
- Author
-
Miller, C., primary, Huston, J., additional, Samu, L., additional, Mfinanga, S., additional, Hopewell, P., additional, and Fair, E., additional
- Published
- 2017
- Full Text
- View/download PDF
19. Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates
- Author
-
Zumla, A, Maeurer, M, Chakaya, J, Hoelscher, M, Ntoumi, F, Rustomjee, R, Vilaplana, C, Yeboah-Manu, D, Rasolofo, V, Munderi, P, Singh, N, Aklillu, E, Padayatchi, N, Macete, E, Kapata, N, Mulenga, M, Kibiki, G, Mfinanga, S, Nyirenda, T, Mboko, L, Garcia-Basteiro, AL, Rakotosamimanana, N, Bates, M, Mwaba, P, Reither, K, Gagneux, S, Edwards, S, Mfinanga, E, Abdulla, S, Cardona, P-J, Russell, JBW, Gant, V, Noursadeghi, M, Elkington, P, Bonnet, M, Menendez, C, Dieye, TN, Diarra, B, Maiga, A, Aseffa, A, Parida, S, Wejse, C, Petersen, E, Kaleebu, P, Oliver, M, Craig, G, Corrah, T, Tientcheu, L, Antonio, M, McHugh, TD, Sheikh, A, Ippolito, G, Ramjee, G, Kaufmann, SHE, Churchyard, G, Steyn, AJC, Grobusch, MP, Sanne, I, Martinson, N, Mandansein, R, Wilkinson, RJ, Wallis, RS, Mayosi, B, and Schito, M
- Subjects
Time Factors ,PULMONARY TUBERCULOSIS ,Immunology ,Antitubercular Agents ,REGIMENS ,Microbiology ,host-directed therapy ,PARTNERSHIPS ,Tuberculosis, Multidrug-Resistant ,DRUGS ,Humans ,MOXIFLOXACIN ,DEVELOPING-COUNTRIES ,Precision Medicine ,SUB-SAHARAN AFRICA ,Host-Directed Therapies Network (HDT-NET) Consortium ,Science & Technology ,treatment ,repurposed drugs ,multi-drug resistant tuberculosis ,Mycobacterium tuberculosis ,11 Medical And Health Sciences ,06 Biological Sciences ,Combined Modality Therapy ,ADJUNCT THERAPIES ,OPPORTUNITIES ,Infectious Diseases ,TRIALS ,tuberculosis ,Life Sciences & Biomedicine - Published
- 2015
20. A Diagnostic and Epidemiologic Investigation of Acute Febrile Illness (AFI) in Kilombero, Tanzania
- Author
-
Hercik, C.A., primary, Cosmas, L., additional, Mogeni, O., additional, Wamola, N., additional, Kohi, W., additional, Ochieng, C., additional, Onyango, C., additional, Fields, B., additional, Mfinanga, S., additional, and Montgomery, J., additional
- Published
- 2016
- Full Text
- View/download PDF
21. Health Beliefs and Patient Perspectives of Febrile Illness in Kilombero, Tanzania
- Author
-
Hercik, C.A., primary, Cosmas, L., additional, Mogeni, O., additional, Kohi, W., additional, Mfinanga, S., additional, Loffredo, C., additional, and Montgomery, J., additional
- Published
- 2016
- Full Text
- View/download PDF
22. Population impact of factors associated with prevalent pulmonary tuberculosis in Tanzania
- Author
-
Senkoro, M., primary, Kumar, A. M. V., additional, Chinnakali, P., additional, Mfinanga, S. G., additional, Egwaga, S., additional, Kamara, V., additional, van Leth, F., additional, and Hinderaker, S. G., additional
- Published
- 2016
- Full Text
- View/download PDF
23. Prevalence of pulmonary tuberculosis in adult population of Tanzania: a national survey, 2012
- Author
-
Senkoro, M., primary, Mfinanga, S., additional, Egwaga, S., additional, Mtandu, R., additional, Kamara, D. V., additional, Basra, D., additional, Fundikira, L., additional, Kahwa, A., additional, Shirima, R., additional, Range, N., additional, Hinderaker, S. G., additional, and van Leth, F., additional
- Published
- 2016
- Full Text
- View/download PDF
24. Screening for pulmonary tuberculosis in a Tanzanian prison and computer-aided interpretation of chest X-rays
- Author
-
Steiner, A., primary, Mangu, C., additional, van den Hombergh, J., additional, van Deutekom, H., additional, van Ginneken, B., additional, Clowes, P., additional, Mhimbira, F., additional, Mfinanga, S., additional, Rachow, A., additional, Reither, K., additional, and Hoelscher, M., additional
- Published
- 2015
- Full Text
- View/download PDF
25. Health care-seeking behaviour among people with cough in Tanzania: findings from a tuberculosis prevalence survey
- Author
-
Senkoro, M., primary, Hinderaker, S. G., additional, Mfinanga, S. G., additional, Range, N., additional, Kamara, D. V., additional, Egwaga, S., additional, and van Leth, F., additional
- Published
- 2015
- Full Text
- View/download PDF
26. National anti-tuberculosis drug resistance study in Tanzania
- Author
-
Chonde, T. M., Basra, D., Mfinanga, S. G. M., Range, N., Lwilla, F., Shirima, R. P., Deun, A., Zignol, M., Cobelens, F. G., Egwaga, S. M., Frank van Leth, Global Health, and Infectious diseases
- Subjects
Bacterial diseases ,Africa, East ,Mycobacterium tuberculosis ,Surveys ,Multidrug resistance ,Assessment ,National ,Tanzania ,Clusters ,Drug resistance ,Retreatment ,Prevalence ,Tuberculosis ,Relapses - Abstract
OBJECTIVE: To assess the prevalence of anti-tuberculosis drug resistance in a national representative sample of tuberculosis (TB) patients in Tanzania according to recommended methodology. DESIGN: Cluster survey, with 40 clusters sampled proportional to size, of notified TB patients from all diagnostic centres in the country. RESULTS: The survey enrolled 1019 new and 148 re-treatment patients. The adjusted prevalence of Mycobacterium tuberculosis strains resistant to any of the four first-line drugs in new patients was 8.3%, while the prevalence of multidrug-resistant TB (MDR-TB) was 1.1%. In retreatment patients, the crude prevalence for any resistance and for MDR-TB was respectively 20.6% and 3.9%. The prevalence of drug resistance did not differ in relapse patients compared to failure patients. These estimates are among the lowest in those African countries with an estimated level of drug resistance in the last 5 years. CONCLUSION: The low levels of drug resistance in Tanzania are likely due to a well performing TB control programme and the absence of noticeable involvement of the private sector in TB treatment
- Published
- 2010
27. Fine needle aspiration cytology and the choice of fixatives in the diagnosis of tuberculous adenitis at Muhimbili National Hospital, Dar-es-Salaam, Tanzania
- Author
-
Mfinanga, S. G., primary, Mwakyoma, H. A., additional, and Maliva, G. S., additional
- Published
- 2010
- Full Text
- View/download PDF
28. Targeted Active Case Finding in Household Contacts of Smear Positive Tuberculosis Patients in a High Incidence Urban Setting
- Author
-
Mutayoba, B., primary, Mfinanga, S., additional, and Morkve, O., additional
- Published
- 2008
- Full Text
- View/download PDF
29. Patterns of Mobile Phone Ownership and Use Among Pregnant Women in Southern Tanzania: Cross-Sectional Survey
- Author
-
Vasudevan, Lavanya, Ostermann, Jan, Moses, Sara Marwerwe, Ngadaya, Esther, and Mfinanga, Sayoki Godfrey
- Subjects
Information technology ,T58.5-58.64 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundThere is a paucity of subnational data on patterns of mobile phone ownership and use in Tanzania to inform the development of digital health interventions. ObjectiveThe aim of this study is to assess patterns of mobile phone ownership and use in pregnant women to inform the feasibility and design of digital health interventions for promoting timely uptake of childhood vaccines in southern Tanzania. MethodsBetween August and November 2017, pregnant women in their third trimester were enrolled at health facilities and from surrounding communities, and asked about their patterns of mobile phone ownership and use in an interviewer administered survey. ResultsOf 406 women, only 3 had never used a phone. Most women (>98%) could make and receive phone calls. Compared to urban women, rural women reported higher mobile phone use rates but were less likely to be sole owners of phones, and less likely to send or receive SMS, transact money, browse the internet, or use social media via mobile phones. ConclusionsThe findings suggest high feasibility for digital health interventions delivered via mobile phones to pregnant women in southern Tanzania. The feasibility of smartphone-based interventions or strategies relying on the use of social media or the internet is limited.
- Published
- 2020
- Full Text
- View/download PDF
30. Patient's dissatisfaction with the public and private laboratory services in conducting HIV related testing in Tanzania.
- Author
-
Mfinanga, S. G., Kahwa, A., Kimaro, G., Kilale, A., Kivuyo, S., Senkoro, M., Ngowi, B., Mtandu, R., Mutayoba, B., Ngadaya, E., and Mashoto, K.
- Subjects
- *
PATIENT satisfaction , *CLINICAL pathology , *DIAGNOSIS of HIV infections , *CROSS-sectional method - Abstract
Background: Patient's satisfaction with both private and public laboratory services is important for the improvement of the health care delivery in any country. Methods: A cross-sectional survey was conducted in 24 randomly selected health facilities with laboratories that are conducting HIV related testing, in Mainland Tanzania. The study assessed patient's satisfaction with the laboratory services where by a total of 295 patients were interviewed. Results: Of data analyzed for a varying totals from 224 to 294 patients, the percentage of dissatisfaction with both public and private laboratory services, ranged from 4.3% to 34.8%, with most of variables being more than 15%. Patients who sought private laboratory services were less dissatisfied with the cleanness (3/72, 4.2%) and the privacy (10/72, 13.9%) than those sought public laboratory service for the same services of cleanness (41/222, 18.5%) and privacy (61/222, 27.5%), and proportional differences were statistically significant (X² = 8.7, p = 0.003 and X² = 5.5, p = 0.01, respectively). Patients with higher education were more likely to be dissatisfied with privacy (OR = 1.8, 95% CI: 1.1-3.1) and waiting time (OR = 2.5, 95% CI: 1.5 - 4.2) in both private and public facilities. Patients with secondary education were more likely to be dissatisfied with the waiting time (OR = 5.2; 95%CI: 2.2-12.2) and result notification (OR = 5.1 95%CI (2.2-12.2) than those with lower education. Conclusion: About 15.0% to 34.8% of patients were not satisfied with waiting time, privacy, results notification cleanness and timely instructions. Patients visited private facilities were less dissatisfied with cleanness and privacy of laboratory services than those visited public facilities. Patients with higher education were more likely to be dissatisfied with privacy and waiting time in both private and public facilities. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
31. Dissatisfaction with the laboratory services in conducting HIV related testing among public and private medical personnel in Tanzania.
- Author
-
Mfinanga, S. G., Kahwa, A., Kimaro, G., Kilale, A., Kivuyo, S., Senkoro, M., Ngowi, B., Mtandu, R., Mutayoba, B., Ngadaya, E., and Mashoto, K.
- Subjects
- *
SATISFACTION , *MEDICAL personnel , *QUALITY of service , *CLINICAL pathology , *CROSS-sectional method , *PSYCHOLOGY - Abstract
Background: A comprehensive care and treatment program requires a well functioning laboratory services. We assessed satisfaction of medical personnel to the laboratory services to guide process of quality improvement of the services. Methodology: A cross-sectional survey in 24 randomly selected health facilities in Mainland Tanzania was conducted to assess the satisfaction of the medical personnel with the laboratory services. Results: Of 235 medical personnel interviewed, 196 were valid for analysis and about one quarter were dissatisfied with the laboratory services. Personnel dissatisfied with the services were 38.3% in timely test result, 24.5% in correct and accurate results and 22.4% in clear complete results. The personnel in public laboratories were more dissatisfied with timely test results (OR = 3.6, 95% CI 1.8, 7.3), correct results (OR = 4.1, 95% CI 1.6, 10.8) and clear complete results (OR = 5.0 95% CI 1.6, 15.2). Personnel dissatisfied with the services in 15 laboratories sending specimens to referral laboratories, varied from 13% in availability of equipment to 57% in timely results feedback from the referral laboratories. Personnel dissatisfied with the services in 14 referral laboratories, varied from 28.6% in properly identified specimen to 42.9% in clear, accurate test request and communication. Conclusion: About one quarter of medical personnel in sending or receiving laboratories were dissatisfied with the services. Comparing the personnel in public and private, the personnel in public laboratories were 4 times more dissatisfied with the timely test and correct results; and 5 times more dissatisfied with clear and complete test results. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
32. Strengthening integration of chronic care in Africa: protocol for the qualitative process evaluation of the integrating and decentralising HIV, diabetes and hypertension trial in Uganda and Tanzania
- Author
-
Van Hout, MC, Bachmann, M, Lazarus, J, Piccio, C, Nyirenda, M, Mfinanga, S, Birungi, J, Shayo, E, Bukenya, D, Okebe, J, and Jaffar, S
- Subjects
RA0421 ,RA - Abstract
Introduction In sub-Saharan Africa (SSA), the burden of non-communicable diseases (NCDs), particularly diabetes mellitus (DM) and hypertension, has increased rapidly in recent years, although HIV infection remains a leading cause of death among young-middle-aged adults. Health service coverage for NCDs remains very low in contrast to HIV, despite the increasing prevalence of comorbidity of NCDs with HIV. There is an urgent need to expand healthcare capacity to provide integrated services to address these chronic conditions.\ud Methods and Analysis: This protocol describes procedures for a qualitative process evaluation of INTE-AFRICA, a cluster-randomised trial comparing integrated health service provision for HIVinfection, DM, and hypertension, to the current stand-alone vertical care. Interviews, focus group discussions, and observations of consultations and other care processes in two clinics (in Tanzania, Uganda) will be used to explore the experiences of stakeholders. These stakeholders will include health service users, policy-makers, healthcare providers, community leaders and members, researchers, nongovernmental (NGO) and international organisations. The exploration will be carried out during the implementation of the project, alongside an understanding of the impact of broader structural and contextual factors.\ud Ethics and Dissemination: Ethical approval was granted by the Liverpool School of Tropical Medicine (UK), the National Institute of Medical Research (Tanzania) and TASO Research Ethics Committee (Uganda) in 2020. The evaluation will provide the opportunity to document the implementation of integration over several timepoints (6, 12 and 18 months) and refine integrated service provision prior to scale-up. This synergistic approach to evaluate, understand and respond will support service integration and inform monitoring, policy and practice development efforts to involve and educate communities in Tanzania and Uganda. It will create a model of care and a platform of good practices and lessons learnt for other countries implementing integrated and decentralised community health services.
33. Survival of HIV-positive and HIV-negative leprosy patients in Mwanza, Tanzania
- Author
-
van den Broek J, Mfinanga S, Candida Moshiro, O'Brien R, and Mugomela A
- Subjects
Adult ,Male ,Survival Rate ,Adolescent ,Leprosy ,Humans ,Female ,HIV Infections ,Middle Aged ,Aged
34. Ethical issues in intervention studies on the management of treatment of diabetes and hypertension in sub-Saharan Africa
- Author
-
Shayo, E, Van Hout, MC, Birungi, J, Garrib, A, Kivuyo, S, Mfinanga, S, Nyirenda, M, Namakoola, I, Okebe, J, Ramiya, K, Bachmann, M, Cullen, W, Lazarus, J, Gill, G, Shiri, T, Bukenya, D, Snell, H, Nanfuka, M, Cuevas, L, Shimwela, M, Mutungi, G, Musinguzi, J, Mghamba, J, Mugisha, K, Jaffar, S, Smith, P, and Sewankambo, N
- Subjects
RA0421 - Abstract
The incidence of diabetes and hypertension has risen sharply in sub-Saharan Africa alongside a continuing high burden of HIV-infection. In many settings, the prevalence figures among adults are 4-5% for diabetes, above 25% for hypertension and 5-20% for HIVinfection. All these conditions require life-long treatment and they have increased substantially the demand for chronic care services in Africa, where health systems have, until recently, focussed on tackling acute infectious diseases.
35. Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania
- Author
-
van den Broek J, Mfinanga S, Candida Moshiro, O'Brien R, Mugomela A, and Lefi M
- Subjects
Adult ,Male ,Surveillance ,Adolescent ,Antitubercular Agents ,HIV Infections ,Survival Analysis ,Tanzania ,Treatment ,Humans ,Regression Analysis ,Tuberculosis ,Female ,Developing Countries - Abstract
Little is known about the outcome of tuberculosis (TB) treatment and subsequent survival of human immunodeficiency virus (HIV) infected patients treated under routine programme conditions in a developing country. We followed a cohort of HIV-positive and HIV-negative tuberculosis patients during therapy and assessed their vital and tuberculosis status 3 years after completion of treatment in Mwanza, Tanzania. Newly diagnosed and relapse tuberculosis cases consecutively registered over a 6-month period were enrolled into an epidemiological study of TB/HIV. Treatment outcome was based on information in tuberculosis treatment registers. Patients surviving treatment were assessed 3 years later by personal interview. Cause of death was determined by verbal autopsy. Of 561 patients enrolled into the study, 505 patients alive at completion of treatment were eligible for assessment at 3 years. Except for mortality, HIV infection was not statistically associated with differing treatment outcomes. At time of follow-up, the overall mortality was 19% and was associated with HIV infection (hazard ratio [hr] 3.7, 95% confidence interval [CI] 2.6-5.2) and age 35 years and over (hr 1.5, 95% CI 1.02-2.1), but not with type of tuberculosis, gender, or initial drug resistance. By life table analysis, probability of survival at 4 years was 35% for HIV-positive patients compared to 90% for HIV-negative patients. Although no relapse cases were diagnosed, verbal autopsy suggested equivalent low rates of relapse in both groups. These results demonstrate the effectiveness of the current approach to the treatment of tuberculosis patients regardless of HIV status. However, HIV-related mortality remains high both during and following completion of treatment, and further studies are needed to determine if this mortality might be reduced by simple interventions which are feasible in developing countries.
36. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.
- Author
-
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., Lesikari, S., Chan, A. K., Stone, N., Kalata, N., Karunaharan, N., Gaskell, K., Peirse, M., Ellis, J., Chawinga, C., Lontsi, S., and Ndong, J. -G.
- Subjects
- *
CRYPTOCOCCUS neoformans , *HIV-positive persons , *PUBLIC health , *FLUCONAZOLE , *AMPHOTERICIN B , *TREATMENT effectiveness , *THERAPEUTICS , *HEALTH - Abstract
The article presents a study testing two treatment strategies for cryptococcal meningitis among a population of HIV-infected adults in Africa. Details are provided on the use of fluconazole and flucytosine or amphotericin B. The authors go on to explain the differences in these treatment strategies compared to the standard use of amphotericin B plus flucytosine as well as the fluconazole monotherapy.
- Published
- 2018
- Full Text
- View/download PDF
37. Use of active management of the third stage of labour in seven developing countries.
- Author
-
Stanton C, Armbruster D, Knight R, Ariawan I, Gbangbade S, Getachew A, Portillo JA, Jarquin D, Marin F, Mfinanga S, Vallecillo J, Johnson H, and Sintasath D
- Abstract
Objective To document the use of active management of the third stage of labour for preventing postpartum haemorrhage and to explore factors associated with such use in seven developing countries. Methods Nationally representative samples of facility-based deliveries were selected and observed to determine the use of active management of the third stage of labour and associated factors. Policies on active management were assessed through document review and interviews with relevant professionals. Findings Use of a uterotonic during the third or fourth stages of labour was nearly universal. Correct use of active management of the third stage of labour was found in only 0.5% to 32% of observed deliveries due to multiple deficiencies in practice. In every country except Indonesia, policies regarding active management were conflicting. Conclusion Developing countries have not targeted decreasing postpartum haemorrhage as an achievable goal; there is little use of active management of the third stage of labour, and policies regarding such management often conflict. Studies are needed to identify the most effective components of active management so that the most efficient package of practices can be promoted. Copyright © 2009 World Health Organization [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
38. Burden of pulmonary tuberculosis and its major determinants: a national prevalence survey in Tanzania
- Author
-
Senkoro, Mbazi, Hinderaker, S. G., van Leth, Franciscus C. M., Mfinanga, S. G., Global Health, and Infectious diseases
- Published
- 2016
39. Comparing the cost-effectiveness of the MPT64-antigen detection test to Xpert MTB/RIF and ZN-microscopy for the diagnosis of Extrapulmonary Tuberculosis: An economic evaluation modelling study.
- Author
-
Hassan S, Mustafa T, Muller W, Torres L, Marijani M, Ngadaya E, Mfinanga S, Lema Y, Grønningen E, Jorstad M, Norheim O, and Robberstad B
- Abstract
Extrapulmonary Tuberculosis (EPTB) poses challenges from patient and health system perspectives. The cost-effectiveness analysis of the Xpert MTB/RIF (Xpert) test to diagnose pulmonary tuberculosis is documented. However, there are no economic evaluations for EPTB. Considering the reported better diagnostic sensitivity of the MPT64 test, this study explored its cost-effectiveness as an alternative diagnostic test. We conducted this economic evaluation to assess the cost-effectiveness of the MPT64 test compared to Xpert and ZN microscopy for EPTB adult patients. We utilised a Markov modelling approach to capture short- and long-term costs and benefits from a health system perspective. For the model inputs, we combined data from our cohort studies in Tanzania and peer-reviewed EPTB literature. We calculated the Incremental Cost Effectiveness Ratio (ICER) by comparing the cost (in USD) of each diagnostic test and Quality Adjusted Life Years (QALYs) as health gain. We found the MPT64 test cost-effective for EPTB diagnosis and absolutely dominated ZN microscopy and Xpert using the baseline model inputs. A scenario analysis showed that the Xpert test might be the most cost-effective at its higher test sensitivity, which corresponds to using it to diagnose lymph node aspirates. The prevalence of HIV among EPTB cases, their probability of treatment, costs of ART, and the probability of the MPT64 test in detecting EPTB patients were the main parameters associated with the highest impact on ICER in one-way deterministic analysis. The most cost-effective option for EPTB at the baseline parameters was the MPT64 diagnostic test. Including the MPT64 test in EPTB diagnostic pathways for previously untreated patients can lead to better resource use. The Xpert test was the most cost-effective diagnostic intervention at a higher diagnostic test sensitivity in scenario analyses based on different sites of infection, such as for the lymph node aspirates., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Hassan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
40. Evaluating the modulation of peripheral immune profile in people living with HIV and (Neuro)cysticercosis.
- Author
-
Lema YL, Prodjinotho UF, Makasi C, Nanyaro MA, Kilale AM, Mfinanga S, Stelzle D, Schmidt V, Carabin H, Winkler AS, Lyamuya EF, Ngowi BJ, Chachage M, and Prazeres da Costa C
- Subjects
- Humans, Male, Adult, Female, Cross-Sectional Studies, Middle Aged, Tanzania epidemiology, Antibodies, Helminth blood, Animals, CD4 Lymphocyte Count, Young Adult, Antigens, Helminth immunology, Antigens, Helminth blood, Neurocysticercosis immunology, Neurocysticercosis complications, HIV Infections complications, HIV Infections immunology, Cytokines blood, Coinfection immunology, Taenia solium immunology
- Abstract
Background: The parasitic infection caused by Taenia solium represents a significant public health concern in developing countries. Larval invasion of body tissues leads to cysticercosis (CC), while central nervous system (CNS) involvement results in neurocysticercosis (NCC). Both conditions exhibit diverse clinical manifestations, and the potential impact of concomitant HIV infection especially prevalent in sub-Saharan Africa on peripheral and CNS immune responses remains poorly understood. This study aimed to identify the potential impact of HIV coinfection in CC and NCC patients., Methodology: A nested study within a cross-sectional analysis in two Tanzanian regions was performed and 234 participants (110 HIV+ and 124 HIV-) were tested for cysticercosis antibodies, antigens, CD4 counts and serum Th1 and Th2 cytokines via multiplex bead-based immunoassay. 127 cysticercosis seropositive individuals underwent cranial computed tomography (CCT) and clinical symptoms were assessed. Multiple regression analyses were performed to identify factors associated with cytokine modulation due to HIV in CC and NCC patients., Results: Serologically, 18.8% tested positive for cysticercosis antibodies, with no significant difference HIV+ and HIV+. A significantly higher rate of cysticercosis antigen positivity was found in HIV+ individuals (43.6%) compared to HIV- (28.2%) (p = 0.016). CCT scans revealed that overall 10.3% had active brain cysts (NCC+). Our study found no significant changes in the overall cytokine profiles between HIV+ and HIV- participants coinfected CC and NCC, except for IL-5 which was elevated in HIV+ individuals with cysticercosis. Furthermore, HIV infection in general was associated with increased levels of pro-and some anti-inflammatory cytokines e.g. TNF-α, IL-8, and IFN-γ. However, based on the interaction analyses, no cytokine changes were observed due to HIV in CC or NCC patients., Conclusions: In conclusion, while HIV infection itself significantly modulates levels of key cytokines such as TNF-α, IL-8, and IFN-γ, it does not modulate any cytokine changes due to CC or NCC. This underscores the dominant influence of HIV on the immune system and highlights the importance of effective antiretroviral therapy in managing immune responses in individuals coinfected with HIV and CC/NCC., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Lema et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
41. Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.
- Author
-
Nkinda L, Barabona G, Ngare I, Nkuwi E, Kamori D, Msafiri F, Kunambi PP, Osati E, Kidenya BR, Chuwa H, Kinasa G, Hassan FE, Judicate GP, Gasper J, Kisuse J, Mfinanga S, Senkoro M, Ueno T, Lyamuya E, and Balandya E
- Subjects
- Humans, Tanzania epidemiology, Male, Female, Adult, Middle Aged, Young Adult, Neutralization Tests, Adolescent, COVID-19 prevention & control, COVID-19 immunology, COVID-19 epidemiology, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral blood, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, SARS-CoV-2 immunology, Vaccination
- Abstract
COVID-19 vaccine became available in Tanzania during the first wave of the Omicron variant. During that time community seroprevalence of SARS-CoV-2 was already at 50%-80%. To date, it remains largely unknown whether ongoing vaccination with the primary series vaccines has any meaningful immune-boosting effects against newer Omicron subvariants. Therefore, we tested cross-neutralizing capacity of antibodies elicited by infection, vaccination, or both against SARS-CoV-2 Omicron subvariants BA.1, and the newer subvariants BQ.1.1 and XBB.1.5. that were unexperienced by this population. Participants who were either SARS-CoV-2 infected-only (n = 28), infected vaccinated (n = 22), or vaccinated-only (n = 73) were recruited from Dar-es-Salaam, Tanzania, between April and December 2022. Plasma 50% neutralization titers (NT
50 ) against SARS-CoV-2 wild-type strain and Omicron subvariants were quantified by a lentiviral-based pseudo-virus assay. Percentage of participants with neutralizing activity against WT and BA.1 was high (>85%) but was reduced against BQ.1.1 (64%-77%) and XBB.1.5 (35%-68%) subvariants. The low median cross-neutralization titer was slightly higher in the infected vaccinated group compared to vaccine-only group against BQ.1.1 (NT50 148 vs. 85, p = 0.032) and XBB.1.5 (NT50 85 vs. 37 p = 0.022) subvariants. In contrast, vaccine-boost among the infected vaccinated did not result to increased cross-neutralization compared to infected-only participants (BQ.1.1 [NT50 of 148 vs. 100, p = 0.501] and XBB.1.5 [NT50 86 vs. 45, p = 0.474]). We report severely attenuated neutralization titers against BQ.1.1 and XBB.1.5 subvariants among vaccinated participants, which marginally improved in the infected vaccinated participants. Our findings call for further studies to evaluate effectiveness of the primary series vaccines in preventing severe infection and mortality against the newer variants., (© 2024 Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
42. Long-term impact of an integrated HIV/non-communicable disease care intervention on patient retention in care and clinical outcomes in East Africa.
- Author
-
Namakoola I, Moyo F, Birungi J, Kivuyo S, Karoli P, Mfinanga S, Nyirenda M, Jaffar S, and Garrib A
- Subjects
- Humans, Female, Male, Adult, Uganda, Tanzania, Middle Aged, Prospective Studies, Noncommunicable Diseases therapy, SARS-CoV-2, HIV Infections therapy, Retention in Care, Delivery of Health Care, Integrated, Hypertension therapy, COVID-19 therapy, COVID-19 epidemiology, Diabetes Mellitus therapy
- Abstract
Objective: To describe rates of retention in care and control of hypertension, diabetes and HIV among participants receiving integrated care services for a period of up to 24 months in East Africa., Methods: Between 5 October 2018 and 23 June 2019 participants enrolled into a prospective cohort study evaluating the feasibility of integrated care delivery for HIV, diabetes and hypertension from a single point of care in Tanzania and Uganda (MOCCA study). Integrated care clinics were established in 10 primary healthcare facilities and care was provided routinely according to national guidelines. Initial follow-up was 12 months. Outcomes were rates of retention in care, proportions of participants with controlled hypertension (blood pressure <140/90 mmHg), diabetes (fasting blood glucose <7.0 mmol/L) and HIV (plasma viral load <1000 copies/ml). The study coincided with the COVID-19 pandemic response. Afterwards, all participants were approached for extended follow-up by a further 12 months in the same clinics. We evaluated outcomes of the cohort at the end of long-term follow-up., Results: The MOCCA study enrolled 2273 participants of whom 1911 (84.5%) were retained in care after a median follow-up of 8 months (Interquartile range: 6.8-10.7). Among these, 1283/1911 (67.1%) enrolled for a further year of follow-up, 458 (24.0%) were unreachable, 71 (3.7%) reverted to vertical clinics (clinics providing services dedicated to study conditions), 31 (1.6%) died and 68 (3.6%) refused participation. Among participants who enrolled for longer follow-up, mean age was 51.4 ± 11.7 years, 930 (72.5%) were female and 509 (39.7%) had multiple chronic conditions. Overall, 1236 (96.3%) [95% confidence interval 95.2%-97.3%] participants were retained in care, representing 1236/2273 (54.3%) [52.3%-56.4%] of participants ever enrolled in the study. Controlled hypertension, diabetes and HIV at the end of follow-up was, 331/618 (53.6%) [49.5%-57.5%], 112/354 (31.6%) [26.8%-36.8%] and 332/343 (96.7%) [94.3%-98.4%] respectively., Conclusion: Integrated care can achieve high rates of retention in care long term, but control of blood pressure and blood sugar remains low., (© 2024 The Authors Tropical Medicine & International Health published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
43. Stability in care and risk of loss to follow-up among clients receiving community health worker-led differentiated HIV care: Results from a prospective cohort study in northern Tanzania.
- Author
-
Abdul R, Rinke de Wit TF, Martelli G, Costigan K, Katambi P, Pozniak A, Maokola W, Mfinanga S, and Hermans S
- Subjects
- Pregnancy, Humans, Female, Male, Tanzania epidemiology, Follow-Up Studies, Prospective Studies, Community Health Workers, HIV Infections drug therapy, Anti-HIV Agents therapeutic use
- Abstract
Background: HIV services in Tanzania are facility-based but facilities are often overcrowded. Differentiated care models (DCM) have been introduced into the National Guidelines. We piloted a Community Health Worker (CHW)-led HIV treatment club model (CHW-DCM) in an urban region, and assessed its effectiveness in comparison to the standard of care (SoC, facility-based model), in terms of stability in care, loss to follow-up (LTFU) and treatment adherence., Methods: In two clinics in the Shinyanga region, clients established on ART (defined as stable clients by national guidelines as on first-line ART >6 months, undetectable viral load, no opportunistic infections or pregnancy, and good adherence) were offered CHW-DCM. This prospective cohort study included all stable clients who enrolled in CHW-DCM between July 2018 and March 2020 (CHW-DCM) and compared them to stable clients who remained in SoC during that period. Multivariable Cox regression models were used to analyse factors associated with continued stability in care and the risk of LTFU during 18 months of follow-up; treatment adherence was assessed by pill count and compared using Chi-square tests., Results: Of 2472 stable clients, 24.5% received CHW-DCM and 75.5% SoC. CHW-DCM clients were slightly older (mean 42.8 vs. 37.9 years) and more likely to be female (36.2% vs. 32.2%). Treatment adherence was better among CHW-DCM than SoC: 96.6% versus 91.9% and 98.5% versus 92.2%, respectively (both p = 0.001). SoC clients were more likely to not remain stable over time than CHW-DCM (adjusted Hazard ratio [AHR] = 2.68; 95% CI: 1.86-3.90). There was no difference in LTFU (adjusted hazard ratio [AHR] = 1.54; 95%CI: 0.82-2.93)., Conclusion: Clients attending CHW-DCM demonstrated better stability in care and treatment adherence than SoC, and the risk of LTFU was not increased. These findings demonstrate the potential of CHW in delivering community-based HIV services in the local Tanzanian context. These results could be used to extend this CHW-DCM model to similar settings., (© 2024 The Authors Tropical Medicine & International Health Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
44. Health insurance financing and patient retention in care at diabetics and hypertension clinics in Dar es Salaam and Pwani regions, Tanzania. A cohort study.
- Author
-
Manisha H, Moshiro C, Hussein A, Amani F, Mshiu J, Shabbar J, and Mfinanga S
- Abstract
Hypertension and diabetes are chronic conditions that cause major morbidity and mortality worldwide. Whether health insurance financing is associated with improved retention in chronic care in Tanzania, is unknown. Our study establishes the effect of health insurance on retention and the determinants for retention in care among patients attending diabetes and hypertension clinics. We used a Cohort design to study participants enrolled in a cluster-randomized trial of integrated management of HIV, diabetes, and hypertension compared with standard vertical care in the INTE-AFRICA trial. Fifteen health facilities in Dar es Salam and Pwani regions were enrolled, with 1716 participants. Our sample size had 95% power to detect a 50% to 60% retention difference between the insured and uninsured groups (95% CI). We compared proportions using χ2 tests and obtained prevalence and rate ratios by Generalised Linear Models. We studied 1716 participants for 1612.3 Person-years (PY). At the study's end, 1351 persons were alive and retained in care. Among the insured participants (26.0%), females accounted for 65.9%. Middle-aged adults contributed 58.8% of insured participants. We observed high retention rates (retention incidence rate IR: 83.80/100 PY; 95% CI (79.40-88.40)). There was no difference in retention among insured and uninsured patients (adjusted rate ratio aRR: 1.00; 95% CI, 0.94-1.06). Being middle-aged or senior-aged adults compared to young adults, having diabetes alone or hypertension alone compared to both conditions, having the comorbidity of diabetes or hypertension with HIV compared to a single condition, and attending health centres and hospitals compared to dispensaries were significantly associated with retention in care. This study showed no effect of health insurance on retention in diabetic and hypertension care clinics. However, age, medical diagnosis, morbidity, and type of health facility attended were associated with retention in care., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Manisha et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
45. Tobacco smoking clusters in households affected by tuberculosis in an individual participant data meta-analysis of national tuberculosis prevalence surveys: Time for household-wide interventions?
- Author
-
Hamada Y, Quartagno M, Law I, Malik F, Bonsu FA, Adetifa IMO, Adusi-Poku Y, D'Alessandro U, Bashorun AO, Begum V, Lolong DB, Boldoo T, Dlamini T, Donkor S, Dwihardiani B, Egwaga S, Farid MN, Garfin AMCG, Gaviola DMG, Husain MM, Ismail F, Kaggwa M, Kamara DV, Kasozi S, Kaswaswa K, Kirenga B, Klinkenberg E, Kondo Z, Lawanson A, Macheque D, Manhiça I, Maama-Maime LB, Mfinanga S, Moyo S, Mpunga J, Mthiyane T, Mustikawati DE, Mvusi L, Nguyen HB, Nguyen HV, Pangaribuan L, Patrobas P, Rahman M, Rahman M, Rahman MS, Raleting T, Riono P, Ruswa N, Rutebemberwa E, Rwabinumi MF, Senkoro M, Sharif AR, Sikhondze W, Sismanidis C, Sovd T, Stavia T, Sultana S, Suriani O, Thomas AM, Tobing K, Van der Walt M, Walusimbi S, Zaman MM, Floyd K, Copas A, Abubakar I, and Rangaka MX
- Abstract
Tuberculosis (TB) and non-communicable diseases (NCD) share predisposing risk factors. TB-associated NCD might cluster within households affected with TB requiring shared prevention and care strategies. We conducted an individual participant data meta-analysis of national TB prevalence surveys to determine whether NCD cluster in members of households with TB. We identified eligible surveys that reported at least one NCD or NCD risk factor through the archive maintained by the World Health Organization and searching in Medline and Embase from 1 January 2000 to 10 August 2021, which was updated on 23 March 2023. We compared the prevalence of NCD and their risk factors between people who do not have TB living in households with at least one person with TB (members of households with TB), and members of households without TB. We included 16 surveys (n = 740,815) from Asia and Africa. In a multivariable model adjusted for age and gender, the odds of smoking was higher among members of households with TB (adjusted odds ratio (aOR) 1.23; 95% CI: 1.11-1.38), compared with members of households without TB. The analysis did not find a significant difference in the prevalence of alcohol drinking, diabetes, hypertension, or BMI between members of households with and without TB. Studies evaluating household-wide interventions for smoking to reduce its dual impact on TB and NCD may be warranted. Systematically screening for NCD using objective diagnostic methods is needed to understand the actual burden of NCD and inform comprehensive interventions., Competing Interests: TSo declares a receipt of funding from the Global Fund for conducting the TB prevalence survey in Mongolia. All other authors declare no competing interests., (Copyright: © 2024 Hamada et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
46. Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Distinguishing Lung Cancer in People with HIV.
- Author
-
Baluku JB, Namiiro S, Namanda B, Nabwana M, Andia-Biraro I, Worodria W, Salata R, Mfinanga S, Gerson S, and Kirenga B
- Subjects
- Humans, Female, Middle Aged, Male, Neutrophils pathology, Retrospective Studies, Platelet Count, Blood Platelets pathology, Lymphocytes pathology, Prognosis, Lung Neoplasms diagnosis, Lung Neoplasms pathology, HIV Infections complications
- Abstract
Objective: The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) demonstrate good diagnostic accuracy in distinguishing lung cancer patients from healthy individuals, primarily in HIV-negative populations. We determined the sensitivity (Se), specificity (Sp), and area under the curve (AUC) of the NLR and PLR in discriminating between people living with HIV (PLWH) with and without lung cancer., Methods: This is a comparative analysis of secondary data. Cases were PLWH with lung cancer from a retrospective cohort treated at the Uganda Cancer Institute. Controls were unmatched PLWH without lung cancer who were randomly selected from three HIV clinics in Uganda. Se, Sp, and AUC analysis and determination of optimal cutoffs were performed using receiver operating characteristic (ROC) curves., Results: Of 115 PLWH (18 cases and 97 controls), 83 (72.2%) were female, 110 (95.7) were on ART, and the median (IQR) age was 46 (38-51) years. The median (IQR) NLR was higher among cases than controls (3.53 (3.14-7.71) vs. 0.92 (0.67-1.09), p < 0.001). Similarly, the PLR was higher among cases than controls (237.5 (177.8-361.6) vs. 123.6 (100.6-155.4), p =0.001). At a cutoff of 2.44, the respective Se, Sp, and AUC of the NLR were 87.5% (95% CI: 61.7%-98.4%), 100% (95% CI: 96.2%-100%), and 0.94 (95% CI: 0.85-1.00, p < 0.001). Similarly, the respective Se, Sp, and AUC for the PLR were 75% (95% CI: 47.6%-92.7%), 87.2% (95% CI: 78.8%-93.2%), and 0.81 (95% CI: 0.70-0.93, p < 0.001) at a cutoff of 196.3., Conclusion: The NLR and PLR discriminated PLWH with and without lung cancer and could be useful in PLWH with respiratory symptoms in whom lung cancer can easily be misdiagnosed as other lung pathology., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2024 Joseph Baruch Baluku et al.)
- Published
- 2024
- Full Text
- View/download PDF
47. Leveraging Community Health Workers and a Responsive Digital Health System to Improve Vaccination Coverage and Timeliness in Resource-Limited Settings: Protocol for a Cluster Randomized Type 1 Effectiveness-Implementation Hybrid Study.
- Author
-
Vasudevan L, Ostermann J, Thielman N, Baumgartner JN, Solomon D, Mosses A, Hobbie A, Hair NL, Liang C, van Zwetselaar M, Mfinanga S, and Ngadaya E
- Abstract
Background: Tanzania is 1 of 20 countries where the majority of unvaccinated and undervaccinated children reside. Prior research identified substantial rural-urban disparities in the coverage and timeliness of childhood vaccinations in Tanzania, with children in rural settings being more likely to receive delayed or no vaccinations. Further research is necessary to identify effective and scalable interventions that can bridge rural-urban gaps in childhood vaccination while accounting for multifaceted barriers to vaccination., Objective: This protocol describes a type 1 effectiveness-implementation hybrid study to evaluate Chanjo Kwa Wakati (timely vaccination in Kiswahili), a community-based digital health intervention to improve vaccination timeliness. The intervention combines human resources (community health workers), low-cost digital strategies (electronic communication, digital case management, and task automation), a vaccination knowledge intervention, and insights from behavioral economics (reminders and incentives) to promote timely childhood vaccinations., Methods: The study will be conducted in 2 predominantly rural regions in Tanzania with large numbers of unvaccinated or undervaccinated children: Shinyanga and Mwanza. Forty rural health facilities and their catchment areas (clusters) will be randomized to an early or delayed onset study arm. From each cluster, 3 cohorts of mother-child dyads (1 retrospective cohort and 2 prospective cohorts) will be enrolled in the study. The timeliness and coverage of all vaccinations recommended during the first year of life will be observed for 1200 children (n=600, 50% intervention group children and n=600, 50% nonintervention group children). The primary effectiveness outcome will be the timeliness of the third dose of the pentavalent vaccine (Penta3). Quantitative surveys, vaccination records, study logs, fidelity checklists, and qualitative interviews with mothers and key informants will inform the 5 constructs of the reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework. The results will be used to develop an implementation blueprint to guide future adaptations and scale-up of Chanjo Kwa Wakati., Results: The study was funded in August 2022. Data collection is expected to last from February 2024 to July 2027., Conclusions: This study will address the lack of rigorous evidence on the effectiveness of community-based digital health interventions for promoting vaccination coverage and timeliness among children from sub-Saharan Africa and identify potential implementation strategies to facilitate the deployment of vaccination promotion interventions in low- and middle-income countries., Trial Registration: ClinicalTrials.gov NCT06024317; https://www.clinicaltrials.gov/study/NCT06024317., International Registered Report Identifier (irrid): PRR1-10.2196/52523., (©Lavanya Vasudevan, Jan Ostermann, Nathan Thielman, Joy Noel Baumgartner, David Solomon, Anna Mosses, Amy Hobbie, Nicole L Hair, Chen Liang, Marco van Zwetselaar, Sayoki Mfinanga, Esther Ngadaya. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 12.01.2024.)
- Published
- 2024
- Full Text
- View/download PDF
48. Management of chronic conditions in resource limited settings: multi stakeholders' perception and experiences with receiving and providing integrated HIV, diabetes and hypertension services in Tanzania.
- Author
-
Shayo EH, Murdoch J, Kiwale Z, Bachmann M, Bakari M, Mbata D, Masauni S, Kivuyo S, Mfinanga S, Jaffar S, and Van Hout MC
- Subjects
- Humans, Tanzania epidemiology, Perception, Chronic Disease, Noncommunicable Diseases epidemiology, Noncommunicable Diseases therapy, HIV Infections therapy, HIV Infections drug therapy, Hypertension epidemiology, Hypertension therapy, Diabetes Mellitus epidemiology, Diabetes Mellitus therapy
- Abstract
Background: The rising prevalence of non-communicable diseases (NCDs) alongside the continuing high burden of HIV poses a serious challenge to middle- and low-income countries' healthcare systems. Pilot studies of integrated models of service delivery for HIV, hypertension and diabetes have demonstrated that they are feasible and acceptable among patients and care providers. This study assessed multi-stakeholders' perspectives of the delivery and receipt of integrated care in Tanzania., Methods: A qualitative process evaluation was conducted in Dar es Salaam region of Tanzania where the integrated service delivery model was implemented from July to November 2021. In-depth interviews were held with seven key informants at the national, regional and district levels, eight healthcare providers, two researchers working at the integrated clinic and forty patients benefiting from integrated services at a large hospital. Three focus group discussions were held with community leaders and residents of the hospital's catchment area, and clinic level observations were conducted. Thematic analysis was conducted followed by the use of Bronfenbrenner's ecological model to identify factors pertinent to sustaining and scaling up of the integrated model., Results: Participants of the study at all levels were aware of the increased prevalence of NCDs specifically for hypertension and diabetes and were concerned about the trend of increasing co-morbid conditions among people living with HIV (PLHIV). The integrated service delivery model was positively perceived by stakeholders because of its multiple benefits for both patients and the healthcare system. These include stigma and discrimination reduction, improved quality of care, efficient use of limited resources, cost and time saving, reduced duplication of services and fostering of early detection for undiagnosed conditions. The organisation of the clinic was critical in increased satisfaction. Several challenges were observed, which included costs for NCD services relative to free care for HIV and inconsistent availability of NCD medications., Conclusion: Stakeholders reported numerous benefits of the integrated service delivery model that are fundamental in improving the health of many Tanzanians living with NCDs and HIV. These benefits highlight the need for policy and decision-makers to sustain and expand the integrated service delivery model as a solution to many challenges facing the health system especially at the primary care level., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
49. Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
- Author
-
Kivuyo S, Birungi J, Okebe J, Wang D, Ramaiya K, Ainan S, Tumuhairwe F, Ouma S, Namakoola I, Garrib A, van Widenfelt E, Mutungi G, Jaoude GA, Batura N, Musinguzi J, Ssali MN, Etukoit BM, Mugisha K, Shimwela M, Ubuguyu OS, Makubi A, Jeffery C, Watiti S, Skordis J, Cuevas L, Sewankambo NK, Gill G, Katahoire A, Smith PG, Bachmann M, Lazarus JV, Mfinanga S, Nyirenda MJ, and Jaffar S
- Subjects
- Female, Humans, Male, Tanzania epidemiology, Anti-HIV Agents therapeutic use, Diabetes Mellitus therapy, Diabetes Mellitus drug therapy, HIV Infections complications, HIV Infections epidemiology, HIV Infections therapy, Hypertension therapy, Hypertension drug therapy
- Abstract
Background: In sub-Saharan Africa, health-care provision for chronic conditions is fragmented. The aim of this study was to determine whether integrated management of HIV, diabetes, and hypertension led to improved rates of retention in care for people with diabetes or hypertension without adversely affecting rates of HIV viral suppression among people with HIV when compared to standard vertical care in medium and large health facilities in Uganda and Tanzania., Methods: In INTE-AFRICA, a pragmatic cluster-randomised, controlled trial, we randomly allocated primary health-care facilities in Uganda and Tanzania to provide either integrated care or standard care for HIV, diabetes, and hypertension. Random allocation (1:1) was stratified by location, infrastructure level, and by country, with a permuted block randomisation method. In the integrated care group, participants with HIV, diabetes, or hypertension were managed by the same health-care workers, used the same pharmacy, had similarly designed medical records, shared the same registration and waiting areas, and had an integrated laboratory service. In the standard care group, these services were delivered vertically for each condition. Patients were eligible to join the trial if they were living with confirmed HIV, diabetes, or hypertension, were aged 18 years or older, were living within the catchment population area of the health facility, and were likely to remain in the catchment population for 6 months. The coprimary outcomes, retention in care (attending a clinic within the last 6 months of study follow-up) for participants with either diabetes or hypertension (tested for superiority) and plasma viral load suppression for those with HIV (>1000 copies per mL; tested for non-inferiority, 10% margin), were analysed using generalised estimating equations in the intention-to-treat population. This trial is registered with ISCRTN 43896688., Findings: Between June 30, 2020, and April 1, 2021 we randomly allocated 32 health facilities (17 in Uganda and 15 in Tanzania) with 7028 eligible participants to the integrated care or the standard care groups. Among participants with diabetes, hypertension, or both, 2298 (75·8%) of 3032 were female and 734 (24·2%) of 3032 were male. Of participants with HIV alone, 2365 (70·3%) of 3365 were female and 1000 (29·7%) of 3365 were male. Follow-up lasted for 12 months. Among participants with diabetes, hypertension, or both, the proportion alive and retained in care at study end was 1254 (89·0%) of 1409 in integrated care and 1457 (89·8%) of 1623 in standard care. The risk differences were -0·65% (95% CI -5·76 to 4·46; p=0·80) unadjusted and -0·60% (-5·46 to 4·26; p=0·81) adjusted. Among participants with HIV, the proportion who had a plasma viral load of less than 1000 copies per mL was 1412 (97·0%) of 1456 in integrated care and 1451 (97·3%) of 1491 in standard care. The differences were -0·37% (one-sided 95% CI -1·99 to 1·26; p
non-inferiority <0·0001 unadjusted) and -0·36% (-1·99 to 1·28; pnon-inferiority <0·0001 adjusted)., Interpretation: In sub-Saharan Africa, integrated chronic care services could achieve a high standard of care for people with diabetes or hypertension without adversely affecting outcomes for people with HIV., Funding: European Union Horizon 2020 and Global Alliance for Chronic Diseases., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
50. Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial.
- Author
-
Garrib A, Kivuyo S, Bates K, Ramaiya K, Wang D, Majaliwa E, Simbauranga R, Charles G, van Widenfelt E, Luo H, Alam U, Nyirenda MJ, Jaffar S, and Mfinanga S
- Subjects
- Adult, Humans, Adolescent, Blood Glucose analysis, Tanzania, Glucose, Fasting, Double-Blind Method, Metformin, Diabetes Mellitus, Type 2, Prediabetic State drug therapy, Glucose Intolerance drug therapy, COVID-19, HIV Infections drug therapy
- Abstract
Aims/hypothesis: In sub-Saharan Africa (SSA), 5% of adults are living with type 2 diabetes and this is rising sharply, with a greater increase among people with HIV. Evidence on the efficacy of prevention strategies in this cohort is scarce. We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA., Methods: Adults (≥18 years old) who were stable in HIV care and found to have prediabetes (IFG and/or IGT) and who were attending hospitals in Dar es Salaam, Tanzania, were randomised to receive sustained-release metformin, 2000 mg daily, or matching placebo between 4 November 2019 and 21 July 2020. Randomisation used permuted blocks. Allocation was concealed in the trial database and made visible only to the Chief Pharmacist after consent was taken. All participants, research and clinical staff remained blinded to the allocation. Participants were provided with information on diet and lifestyle and had access to various health information following the start of the coronavirus disease 2019 (COVID-19) pandemic. Participants were followed up for 12 months. The primary outcome measure was capillary blood glucose measured 2 h following a 75 g glucose load. Analyses were by intention-to-treat., Results: In total, 364 participants (182 in each arm) were randomised to the metformin or placebo group. At enrolment, in the metformin and placebo arms, mean fasting glucose was 6.37 mmol/l (95% CI 6.23, 6.50) and 6.26 mmol/l (95% CI 6.15, 6.36), respectively, and mean 2 h glucose levels following a 75 g oral glucose load were 8.39 mmol/l (95% CI 8.22, 8.56) and 8.24 mmol/l (95% CI 8.07, 8.41), respectively. At the final assessment at 12 months, 145/182 (79.7%) individuals randomised to metformin compared with 158/182 (86.8%) randomised to placebo indicated that they had taken >95% of their medicines in the previous 28 days (p=0.068). At this visit, in the metformin and placebo arms, mean fasting glucose levels were 6.17 mmol/l (95% CI 6.03, 6.30) and 6.30 mmol/l (95% CI 6.18, 6.42), respectively, and mean 2 h glucose levels following a 75 g oral glucose load were 7.88 mmol/l (95% CI 7.65, 8.12) and 7.71 mmol/l (95% CI 7.49, 7.94), respectively. Using a linear mixed model controlling for respective baseline values, the mean difference between the metformin and placebo group (metformin-placebo) was -0.08 mmol/l (95% CI -0.37, 0.20) for fasting glucose and 0.20 mmol/l (95% CI -0.17, 0.58) for glucose levels 2 h post a 75 g glucose load. Weight was significantly lower in the metformin arm than in the placebo arm: using the linear mixed model adjusting for baseline values, the mean difference in weight was -1.47 kg (95% CI -2.58, -0.35). In total, 16/182 (8.8%) individuals had a serious adverse event (Grade 3 or Grade 4 in the Division of Acquired Immunodeficiency Syndrome [DAIDS] adverse event grading table) or died in the metformin arm compared with 18/182 (9.9%) in the placebo arm; these events were either unrelated to or unlikely to be related to the study drugs., Conclusions/interpretation: Blood glucose decreased over time in both the metformin and placebo arms during the trial but did not differ significantly between the arms at 12 months of follow up. Metformin therapy was found to be safe for use in individuals with HIV and prediabetes. A larger trial with longer follow up is needed to establish if metformin can be safely used for the prevention of diabetes in people who have HIV., Trial Registration: The trial is registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry ( www.isrctn.com/ ), registration number: ISCRTN76157257., Funding: This research was funded by the National Institute for Health Research using UK aid from the UK Government to support global health research., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.